

Almirall joins BIOMAP as a new partner to advance the field of inflammatory skin conditions

- **BIOMAP is a European research project from the Innovative Medicines Initiative (IMI) focused on the two most common inflammatory skin conditions: atopic dermatitis and psoriasis**
- **Based on clinical and molecular profiling, the project aims to improve understanding on patient subpopulations, disease mechanisms and outcomes, as well as to deliver biomarkers that identify disease trajectories and treatment response. Its objective is to have a broad impact on patient care and future therapies**
- **The company will provide biosignatures operating in the different stages of atopic dermatitis patients; coordinate bioanalysis of BIOMAP samples, and contribute its scientific, dermatological, and data analysis expertise to the project**

BARCELONA, Spain. June 17, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, has joined **BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis)**, the first dermatology project of the **European Innovative Medicines Initiative (IMI)**, to advance the field of the **two most common inflammatory skin conditions** and improve the lives of patients affected by them. The company will provide biosignatures operating in the different stages of atopic dermatitis patients (skin immune cell composition, skin transcriptome, and systemic biomarkers) and coordinate bioanalysis of BIOMAP samples.

Almirall will also participate in the project by contributing its scientific, dermatological, and data analysis expertise to help BIOMAP examine the underlying causes and mechanisms of atopic dermatitis and psoriasis. The public-private consortium aims to shed new light on the underlying causes of both diseases, as well as the genetic and environmental factors that influence how a patient's disease will progress and how well they will respond to a given treatment.

The IMI project will study data and samples from 50,000 patients, alongside healthy individuals, and perform advanced molecular investigations at the single cell level and in the tissue context with the aim to identify biomarkers for variations in disease outcome. Ultimately, BIOMAP wants to identify new sub-types of the diseases that will allow clinicians and patients to make better, more personalised decisions on treatments.

Atopic dermatitis and psoriasis are serious skin diseases that affect over 300 million people globally. By addressing key unmet needs in treating them, the partnership has the objective to have a broad impact on disease understanding, patient care and future therapies. Almirall places its focus on Medical Dermatology and atopic dermatitis and psoriasis are two of its core skin disease areas. The company's R&D efforts are geared towards providing new options for underserved patients who are struggling with symptoms that affect their wellbeing and quality of life.

“Almirall feels a deep sense of responsibility as a leading company in Medical Dermatology. We strongly believe that we have the opportunity to use our skills and expertise to tangibly improve the daily life of our patients”, states Thomas Huber, PhD, Research Director at Almirall. “Joining the BIOMAP project will allow us to work together to deepen our understanding of key inflammatory diseases and reinforce our commitment to addressing unmet needs and treating them”, he adds.

The BIOMAP project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 821511. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit [almirall.com](https://www.almirall.com)

Media contact:

Tinkle
Pilar Colomer
pcolomer@tinkle.es
Phone: (+34) 93 545 12 51

Investors’ Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact:

Almirall
Maria Duro
maria.duro@almirall.com
Phone: (+34) 671 580 492

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication, click [here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.